Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 11, 2025 · Filed Nov 14, 2025
A board member of ResMed| sold $122K of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$121,872
Shares × reported transaction price
12 days after results of Oct 30, 2025, 79 days before results of Jan 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $252.43 on Nov 11, 2025, 23% above its 52-week low and 14% below its high, after an 8% drop over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 54% of the way up, from 250 adjusted closes. 30 trading days earlier: $273.73 on Sep 30, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.6% | -1.9% | +4.5% |
| 30 days | +3.5% | +1.3% | +2.2% |
| 90 days | +0.5% | +1.4% | -0.9% |
| 180 days | -17.2% | +10.5% | -27.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.